Phase 3 Failure Leads to Full R&D Halt and Restructuring at U.S. Biotech

Theravance Biopharma, Inc. (NASDAQ: TBPH) has halted development of its neurogenic orthostatic hypotension therapy ampreloxetine for multiple system atrophy patients after the Phase 3 CYPRESS study failed to meet its primary endpoint. The company said it will accelerate a strategic review, including a potential sale.

To align with this decision, Thermavance will dismantle its R&D organization, cut operating expenses by roughly 60 percent versus 2025 levels and reduce headcount by about half, while refocusing resources on its respiratory franchise, YUPELRI.

The company expects to hold approximately $400 million in cash (around KRW 500 billion) by the end of Q1 2026, and aims to generate annual cash‐flow of $60 million–$70 million (KRW 80 billion–KRW 90 billion) beginning in Q3 2026.

In Q2 2025, Thermavance monetized its remaining TRELEGY inhalation royalties, selling them to GSK for $225 million (roughly KRW 300 billion), bolstering its cash position. Strong YUPELRI sales that quarter also drove record revenue and delivered non-GAAP breakeven.

Theravance Biopharma is a mid-size biotech that co-promotes YUPELRI for respiratory diseases with global partner Viatris under a profit-sharing agreement, while concurrently developing treatments for rare autonomic disorders.

In the U.S. biotech sector, late-stage trial setbacks are prompting widespread restructuring—R&D downsizing, layoffs, asset sales and M&A reviews—signaling an industry‐wide strategic shift.